Search Results - "NOGA, Stephen"

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma by Kumar, Shaji, Flinn, Ian, Richardson, Paul G., Hari, Parameswaran, Callander, Natalie, Noga, Stephen J., Stewart, A. Keith, Turturro, Francesco, Rifkin, Robert, Wolf, Jeffrey, Estevam, Jose, Mulligan, George, Shi, Hongliang, Webb, Iain J., Rajkumar, S. Vincent

“…Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant efficacy. This randomized…”
Get full text

Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy by Merola, David, Yong, Candice, Noga, Stephen J, Shermock, Kenneth M

“…The use of novel drug agents in the treatment of multiple myeloma (MM) has been associated with improved therapeutic outcomes and survival; however, MM…”
Get full text

Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type by Weinstein, Cindy, Jordan, Karin, Green, Stuart, Khanani, Saleem, Beckford-Brathwaite, Elizabeth, Vallejos, Waldimir, Pong, Annpey, Noga, Stephen J, Rapoport, Bernardo L

“…Results from a phase III, randomized, double-blind, active comparator-controlled, parallel-group trial evaluating fosaprepitant for the prevention of…”
Get full text

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial by Guo, Ying, Jones, Desiree, Palmer, J. Lynn, Forman, Arthur, Dakhil, Shaker R., Velasco, Maria R., Weiss, Matthias, Gilman, Paul, Mills, G. M., Noga, Stephen J., Eng, Cathy, Overman, Michael J., Fisch, Michael J.

“…Objectives Chemotherapy-induced peripheral neuropathy is frequently a dose-limiting factor in cancer treatment and may cause pain and irreversible function…”
Get full text

Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States by Sanchez, Larysa, Chari, Ajai, Cheng, Mu, Cherepanov, Dasha, DerSarkissian, Maral, Huang, Fei, Stull, Dawn Marie, Dabora, Jonathan, Young, Melanie, Noga, Stephen J, Pi, Selina, Zhang, Melody, Banatwala, Azeem, Duh, Mei Sheng, Ailawadhi, Sikander

“…Economic differences among currently available proteasome inhibitors (PI)-based lenalidomide-dexamethasone (Rd)-backbone triplet regimens-ixazomib (I),…”
Get full text

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management by Rifkin, Robert M., Girnius, Saulius K., Noga, Stephen J., Birhiray, Ruemu E., Kambhampati, Suman, Manda, Sudhir, Lyons, Roger M., Yimer, Habte A., Cherepanov, Dasha, Lloyd, Eric, Whidden, Presley, Richter, Joshua

“…Long-term proteasome inhibitor (PI) treatment can improve multiple myeloma (MM) outcomes, but this can be difficult to achieve in clinical practice due to…”
Get full text

Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States by Hari, Parameswaran, Romanus, Dorothy, Palumbo, Antonio, Luptakova, Katarina, Rifkin, Robert M., Tran, Linh Mai, Raju, Aditya, Farrelly, Eileen, Noga, Stephen J., Blazer, Marlo, Chari, Ajai

“…Despite the emerging paradigm favoring continuous therapy, we found that in routine clinical care, myeloma patients at first relapse frequently discontinue…”
Get full text

Treating Multiple Myeloma Patients with Oral Therapies by Kumar, Shaji, Vij, Ravi, Noga, Stephen J, Berg, Deborah, Brent, Lonnie, Dollar, Lawrence, Chari, Ajai

“…Abstract Recent advances have highlighted the importance of long-term, continuous treatment in multiple myeloma (MM) to improve survival. However, treatment…”
Get full text

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial by Weinstein, Cindy, Jordan, Karin, Green, Stuart A., Camacho, Elber, Khanani, Saleem, Beckford-Brathwaite, Elizabeth, Pong, Annpey, Noga, Stephen J., Rapoport, Bernardo L.

“…Purpose Fosaprepitant improved prevention of chemotherapy-induced nausea and vomiting (CINV) in a randomized, double-blind phase III trial (PN031). This post…”
Get full text

Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers by Spielberger, Ricardo, Stiff, Patrick, Bensinger, William, Gentile, Teresa, Weisdorf, Daniel, Kewalramani, Tarun, Shea, Thomas, Yanovich, Saul, Hansen, Keith, Noga, Stephen, McCarty, John, LeMaistre, C. Frederick, Sung, Eric C, Blazar, Bruce R, Elhardt, Dieter, Chen, Mon-Gy, Emmanouilides, Christos

“…Oral mucositis can be a debilitating and dangerous adverse effect of the chemoradiation used to prepare patients for bone marrow transplantation. Palifermin, a…”
Get full text

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib by Manda, Sudhir, Yimer, Habte A., Noga, Stephen J., Girnius, Saulius, Yasenchak, Christopher A., Charu, Veena, Lyons, Roger, Aiello, Jack, Bogard, Kimberly, Ferrari, Renda H., Cherepanov, Dasha, Demers, Brittany, Lu, Vickie, Whidden, Presley, Kambhampati, Suman, Birhiray, Ruemu E., Jhangiani, Haresh S., Boccia, Ralph, Rifkin, Robert M.

“…The ongoing US MM-6 study is investigating in-class transition (iCT) from parenteral bortezomib-based induction to all-oral IRd…”
Get full text

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma by Berenson, James R., Yellin, Ori, Bessudo, Alberto, Boccia, Ralph V., Noga, Stephen J., Gravenor, Donald S., Patel‐Donnelly, Dipti, Siegel, Robert S., Kewalramani, Tarun, Gorak, Edward J., Nassir, Youram, Swift, Regina A., Mayo, Debra

“…Summary Bendamustine, active in multiple myeloma (MM), is a bifunctional mechlorethamine derivative with alkylating properties. Bortezomib, approved to treat…”
Get full text

A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial by Sierra, Jorge, Szer, Jeffrey, Kassis, Jeannine, Herrmann, Richard, Lazzarino, Mario, Thomas, Xavier, Noga, Stephen J, Baker, Nigel, Dansey, Roger, Bosi, Alberto

“…Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound…”
Get full text

PB2089: IN‐CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM‐6 by Girnius, Saulius K., Richter, Joshua, Lyons, Roger M., Bogard, Kimberly, Manda, Sudhir, Birhiray, Ruemu E., Yimer, Habte A., Tran, Kim, Kambhampati, Suman, Arora, Jyoti, Noga, Stephen, Rifkin, Robert

Get full text

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma by Berenson, James R., Hilger, James D., Yellin, Ori, Boccia, Ralph V., Matous, Jeffrey, Dressler, Kenneth, Ghazal, Hassan H., Jamshed, Saad, Kingsley, Edwin C., Harb, Wael A., Noga, Stephen J., Nassir, Youram, Swift, Regina A., Vescio, Robert

“…Panobinostat is a histone deacetylase inhibitor that has shown synergistic preclinical anti-myeloma activity when combined with other agents, recently…”
Get full text

Treatment (tx) Patterns & Outcomes by Line of Therapy (LOT) in a Large United States (US) Cohort of Transplant-Ineligible Patients (pts) with Multiple Myeloma in the Era of Novel Agents by Romanus, Dorothy, Raju, Aditya, Seal, Brian, Farrelly, Eileen, Noga, Stephen J, Blazer, Marlo, Parameswaran, Hari

Get full text

Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use by Ozer, Howard, Mirtsching, Barry, Rader, Michael, Luedke, Susan, Noga, Stephen J., Ding, Beiying, Dreiling, Lyndah

“…Learning Objectives After completing this course, the reader will be able to: Describe the incidence of neutropenia‐related endpoints when pegfilgrastim was…”
Get full text

Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib by Sood, Raman, Carloss, Harry, Kerr, Robert, Lopez, Jose, Lee, Martin, Druck, Mark, Walters, Ian B., Noga, Stephen J.

“…This clinical trial was conducted to determine the safety and efficacy of bortezomib retreatment in patients with multiple myeloma (MM) who had previously…”
Get full text

Association Between Treatment Regimen Type in Second-Line Therapy (2LT) and Duration of Therapy (DOT) & Time To Next Treatment (TTNT) in a United States (US) Relapsed/Refractory Multiple Myeloma (RRMM) Cohort by Romanus, Dorothy, Raju, Aditya, Yong, Candice, Farrelly, Eileen, Luptakova, Katarina, Labotka, Richard, Seal, Brian, Noga, Stephen J, Blazer, Marlo, Parameswaran, Hari

Get full text

Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s Lymphoma by AKPEK, Görgün, AMBINDER, Richard F, FUCHS, Ephraim, FLINN, Ian W, O'DONNELL, Paul, SEIFTER, Eric J, MANN, Risa B, JONES, Richard J, PIANTADOSI, Steven, ABRAMS, Ross A, BRODSKY, Robert A, VOGELSANG, Georgia B, ZAHURAK, Marianna L, FULLER, Donald, MILLER, Carole B, NOGA, Stephen J

“…To evaluate the long-term outcome after allogeneic (allo) and autologous (auto) blood or marrow transplantation (BMT) in patients with relapsed or refractory…”
Get full text